MNPR
NASDAQ · Biotechnology
Monopar Therapeutics Inc
$63.86
+6.98 (+12.27%)
Open$56.95
Previous Close$56.88
Day High$64.28
Day Low$56.81
52W High$105.00
52W Low$28.40
Volume—
Avg Volume125.3K
Market Cap417.79M
P/E Ratio—
EPS$-1.82
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-35.3% upside
Current
$63.86
$63.86
Target
$41.31
$41.31
$22.89
$41.31 avg
$45.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 251.96M | 240.93M | 249.50M |
| Net Income | -49,856,785 | -48,544,141 | -56,777,530 |
| Profit Margin | -19.8% | -20.2% | -22.8% |
| EBITDA | -96,691,861 | -80,803,710 | -82,101,366 |
| Free Cash Flow | -37,656,070 | -41,639,536 | -51,685,705 |
| Rev Growth | +2.3% | +24.0% | -9.1% |
| Debt/Equity | 0.25 | 0.23 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |